<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7315836\results\search\testTrace\results.xml">
  <result pre="viral entry and replication. Being the first step in the" exact="infection" post="process, the entry of pathogenic viruses into susceptible cells"/>
  <result pre="analysis, and intervention at the RBD-ACE2 interface can potentially disrupt" exact="infection" post="efficiency. Recently the cryo-EM and crystal structures of SARS-CoV-2â€™s"/>
  <result pre="IC50 values of 4.30, 6.99, and 1.88 nM, respectively. Additional" exact="immunofluorescence" post="assay (IFA) studies with S-protein-pseudotyped retroviruses, revealed a novel"/>
  <result pre="(IFA) studies with S-protein-pseudotyped retroviruses, revealed a novel mechanism of" exact="infection" post="inhibition of Vero E6 cells by SP-10.37 Structural investigation"/>
  <result pre="Monoclonal antibodies (mAb) have potential applications for diagnosis, prophylaxis, and" exact="treatment" post="of established and evolving viral infections.39âˆ’41 Prabhakar et al."/>
  <result pre="40 mg/kg of mAb 201 or mAb 68 before SARS-CoV" exact="infection" post="showed complete protection from reinfection of lung tissues.43,44 Cross-reactivity"/>
  <result pre="received 200 Î¼g of m396 were nearly completely protected from" exact="infection" post="by Urbani and GD03 virus strains.46 M396 did compete"/>
  <result pre="and could have, therefore, useful applications for diagnosis, prophylaxis, and" exact="treatment" post="of SARS-CoV-2.47 Using the VelocImmune platform, Pascal et al."/>
  <result pre="that their protection might be more effective in a prophylactic" exact="treatment" post="process rather than treatment of MERS-CoV.49 In the latest"/>
  <result pre="be more effective in a prophylactic treatment process rather than" exact="treatment" post="of MERS-CoV.49 In the latest attempt, Chen et al."/>
  <result pre="cross-neutralizing activity of SARS-CoV-S protein and SARS-CoV-2-S protein pseudotyped VSV" exact="infection" post="with IC50 values of 0.19 and 0.57 Î¼M, respectively.51"/>
  <result pre="ACE2 administrated with 0.3 mg of Ig1 ab1 prior intranasal" exact="infection" post="with SARS-CoV-2 did not show any detectable replication-competent virus,"/>
  <result pre="urgent need to develop specific ACE2 inhibitors that would prevent" exact="infection" post="by both SARS-CoV and SARS-CoV-2. One of the first"/>
  <result pre="2) could target ACE2, and showed antiviral activity against SARS-CoV" exact="infection" post="in vitro, with an EC50 value of 41.6 Î¼M,"/>
  <result pre="inhibitors have inherent caveats concerning their use as drugs.64 Therefore," exact="screening" post="for small molecule inhibitors, guided by information gleaned from"/>
  <result pre="is carried out in clinical research in China for the" exact="treatment" post="of SARS-CoV-2 (ChiCTR2000029609).69Hydroxychloroquine (5) is an analogue of chloroquine,"/>
  <result pre="Protein Membrane fusion is a crucial step in the MERS/SARS" exact="infection" post="cycle in both described pathways (see section 1). Within"/>
  <result pre="to region HR2 within the HR. HR2-8 displayed in an" exact="infection" post="inhibition assay with pseudotyped SARS-CoV S protein in Vero"/>
  <result pre="and Table 2).84 Moreover, HR2-8 demonstrated concentration-dependent inhibition of HCoV-NL63" exact="infection" post="with an IC50 value of 0.5 Î¼M and a"/>
  <result pre="spanning residues 1251â€&quot;1286 in HR2 domains, could effectively inhibit MERS-CoV" exact="infection" post="and S protein-mediated membrane fusion (Figure 7 and Table"/>
  <result pre="intranasal administration to Ad5/hDPP4 transgenic mice protected them from MERS-CoV" exact="infection" post="and reduced the lung viral titers by more than"/>
  <result pre="the lung viral titers by more than 1000-fold. Moreover, combination" exact="treatment" post="with IFN-Î² was demonstrated to enhance the protective effect.89"/>
  <result pre="the antiviral activity of EK1 against HCoV-OC43, HCoV-NL63, and HCoV-229E" exact="infection" post="with IC50 values of 1.81, 6.02, and 3.35 Î¼M,"/>
  <result pre="received 5 mg/kg of EK1 were nearly completely protected from" exact="infection" post="by HCoV-OC43 and 200 Î¼g of EK1 against MERS-CoV"/>
  <result pre="potent inhibitory activity inhibit SARS-CoV-2 S-mediated membrane fusion and pseudovirus" exact="infection" post="with IC50 values of 1.3 and 15.8 nM, The"/>
  <result pre="received 0.5 mg/kg of EK1C4 were nearly completely protected from" exact="infection" post="by HCoV-OC43. These data suggested that EK1C4 could be"/>
  <result pre="data suggested that EK1C4 could be used for inhibition and" exact="treatment" post="of infection by currently circulating SARS-CoV-2.92 MERS-5HB, a polypeptide"/>
  <result pre="that EK1C4 could be used for inhibition and treatment of" exact="infection" post="by currently circulating SARS-CoV-2.92 MERS-5HB, a polypeptide derived from"/>
  <result pre="peptide Fuzeon (T20), the only approved fusion inhibitor for HIV-1" exact="treatment" post="to date.93 Therefore, HR derived peptides highlight a promising"/>
  <result pre="Î¼M. In addition, 229E-HR2P potentially inhibited pseudotyped and live HCoV-229E" exact="infection" post="with IC50 values of 0.5 and 1.7 Î¼M, respectively.94"/>
  <result pre="represent a promising strategy.99,100 Xu et al. developed a two-step" exact="screening" post="method to identify inhibitors that potentially block SARS-CoV entry"/>
  <result pre="Zhao et al. demonstrated that 15 could also inhibit MERS-CoV" exact="infection" post="in a pseudovirus-based inhibition assay, with an IC50 value"/>
  <result pre="Wang et al. identified that 16 efficiently inhibited SARS-CoV-2 virus" exact="infection" post="in vitro with an IC50 value of 4.11 Î¼M,"/>
  <result pre="clinical pilot trial conducted with 36 patients with SARS-CoV-2 virus" exact="infection" post="received 400 mg 16 three times a day for"/>
  <result pre="host cellular cathepsin L protease plays a key role in" exact="infection" post="efficiency by activation of the S protein into a"/>
  <result pre="In light of its vital role in the SARS CoV" exact="infection" post="cycle, cathepsin L is a desirable target to interfere"/>
  <result pre="5I4H. Teicoplanin is a glycopeptide antibiotic, with applications in the" exact="treatment" post="of serious infections caused by Gram-positive bacteria such as"/>
  <result pre="of 273 nM) showed some inhibition activity for Ebola virus" exact="infection" post="(EC50 value of 193 nM) of human embryonic kidney"/>
  <result pre="Î¼M. This data offers a new promising point for the" exact="treatment" post="of SARS and Ebola virus infections.114 Recently, in a"/>
  <result pre="a cathepsin inhibitor) and 22. The results suggested that simultaneous" exact="treatment" post="with EST and 22 remarkably blocked infection (&amp;gt;95%).116 Similarly,"/>
  <result pre="suggested that simultaneous treatment with EST and 22 remarkably blocked" exact="infection" post="(&amp;gt;95%).116 Similarly, PÃ¶hlmann et al. reported that 22 could"/>
  <result pre="inhibition.119Chlorpromazine (25Table 5) is an antipsychotic drug developed for the" exact="treatment" post="of schizophrenia. It has also been reported to inhibit"/>
  <result pre="of schizophrenia. It has also been reported to inhibit the" exact="infection" post="of hepatic C virus (HCV),120 mouse hepatitis virus (MHV-2),27"/>
  <result pre="5.1 Î¼M, respectively.126 Phenotypic Screening for New Entry Inhibitors Phenotypic" exact="screening" post="methods are usually used to identify first-in-class drugs without"/>
  <result pre="target and mechanism of action of the drug, while target-based" exact="screening" post="identifies best-in-class drugs.127âˆ’129 Although the phenotypic screening approach often"/>
  <result pre="drug, while target-based screening identifies best-in-class drugs.127âˆ’129 Although the phenotypic" exact="screening" post="approach often is limited in terms of capacity compared"/>
  <result pre="similar HTS approach was employed by Zhang et al. for" exact="screening" post="a compound library consisting of 727 structurally diverse small"/>
  <result pre="virusâ€&quot;cell membrane fusion event. SARS-CoV-2 and other coronaviruses have similar" exact="infection" post="mechanisms. This is especially true for SARS-CoV and CoV-NL63,"/>
  <result pre="for COVID-19 treatment. Passive immunization was well established for viral" exact="infection" post="prophylaxis.138 By meta-analysis of studies about the 1918 influenza,"/>
  <result pre="about the 1918 influenza, H1N1 influenza epidemic demonstrated that early" exact="treatment" post="of convalescent blood products decreased the risk ratio caused"/>
  <result pre="human coronaviruse HTS high-throughput screen HCV hepatic C virus IFA" exact="immunofluorescence" post="assay KM immunized Kunming MERS-CoV Middle East respiratory syndrome"/>
  <result pre="N-terminal domain PD proteolytic domain PBPK physiologically based pharmacokinetic PCR" exact="polymerase chain reaction" post="RMSD root-mean-square deviation RBD receptor-binding domain RdRp RNA-dependent RNA"/>
  <result pre="2020, 988345, 10.1101/2020.03.14.988345. ShiratoK.; KawaseM.; MatsuyamaS.Middle East respiratory syndrome coronavirus" exact="infection" post="mediated by the transmembrane serine protease TMPRSS2. J. Virol.2013,"/>
  <result pre="XuS.; LiuW. R.Learning from the past: possible urgent prevention and" exact="treatment" post="options for severe acute respiratory infections caused by 2019-nCoV."/>
  <result pre="CoughlinM. M.; BabcookJ.; PrabhakarB. S.Human monoclonal antibodies to SARS-coronavirus inhibit" exact="infection" post="by different mechanisms. Virology2009, 394, 39â€&quot;46. 10.1016/j.virol.2009.07.028.19748648 GreenoughT. C.;"/>
  <result pre="StahlN.; LipsichL.; KyratsousC. A.; FeldmannH.Prophylactic and yherapeutic efficacy of mAb" exact="treatment" post="against MERS-CoV in common marmosets. Antiviral Res.2018, 156, 64â€&quot;71."/>
  <result pre="G.; NicholS. T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spread. Virol. J.2005, 2, 6910.1186/1743-422X-2-69.16115318 WangM.; CaoR.; ZhangL.;"/>
  <result pre="GaoJ.; TianZ.; YangX.Breakthrough: chloroquine phosphate has shown apparent efficacy in" exact="treatment" post="of COVID-19 associated pneumonia in clinical studies. BioSci. Trends2020,"/>
  <result pre="KeanW. F.Therapy and pharmacological properties of hydroxychloroquine and chloroquine in" exact="treatment" post="of systemic lupus erythematosus, rheumatoid arthritis and related diseases."/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin."/>
  <result pre="StasP.; FaesD.; NoyensP.Conduction disorder and qt prolongation secondary to long-term" exact="treatment" post="with chloroquine. Int. J. Cardiol.2008, 127, e80â€&quot;e82. 10.1016/j.ijcard.2007.04.055.17590456 YaylaliS."/>
  <result pre="mice. Exp. Physiol.2008, 93, 543â€&quot;548. 10.1113/expphysiol.2007.040048.18448662 KilianskiA.; BakerS. C.Cell-based antiviral" exact="screening" post="against coronaviruses: developing virus-specific and broad-spectrum inhibitors. Antiviral Res.2014,"/>
  <result pre="M. E.; RottierP. J. M.Severe acute respiratory syndrome coronavirus (SARS-CoV)" exact="infection" post="inhibition using spike protein heptad repeat-derived peptides. Proc. Natl."/>
  <result pre="F.; DijkmanR.; RottierP.; van der HoekL.Inhibition of human coronavirus NL63" exact="infection" post="at early stages of the replication cycle. Antimicrob. Agents"/>
  <result pre="QinC.; SunF.; ShiZ. L.; ZhuY.; JiangS. B.; LuL.Inhibition of SARS-CoV-2" exact="infection" post="(previously 2019-nCoV) by a highly potent pan-coronavirus fusion inhibitor"/>
  <result pre="Discovery2020, 6, 2810.1038/s41421-020-0169-8.32373347 VankadariN.Arbidol: A Potential antiviral drug for the" exact="treatment" post="of SARS-CoV-2 by blocking trimerization of the spike glycoprotein."/>
  <result pre="L blocks severe acute respiratory syndrome and ebola pseudotype virus" exact="infection" post="into human embryonic kidney 293T cells. Mol. Pharmacol.2010, 78,"/>
  <result pre="116, 76â€&quot;84. 10.1016/j.antiviral.2015.01.011.25666761 KawaseM.; ShiratoK.; van der HoekL.; TaguchiF.; MatsuyamaS.Simultaneous" exact="treatment" post="of human bronchial epithelial cells with serine and cysteine"/>
  <result pre="site in the spike protein of SARS-CoV-2 is essential for" exact="infection" post="of human lung cells. Mol. Cell2020, 78, 779â€&quot;784. 10.1016/j.molcel.2020.04.022.32362314"/>
  <result pre="J.; HensleyL. E.; FriemanM. B.Repurposing of clinically developed drugs for" exact="treatment" post="of middle east respiratory syndrome coronavirus infection. Antimicrob. Agents"/>
 </snippets>
</snippetsTree>
